SCHEMBL13514019

SCHEMBL13514019

OCCNc1cc(-n2cnc(Nc3ccccc3)n2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.46
▸ MCL1 Q07820 1/20 0.46
▸ GBA1 P04062 1/20 0.42
▸ KCNH3 Q9ULD8 3/20 0.40
▸ HTT P42858 2/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ CDK1 P06493 5/20 0.38
▸ CDK2 P24941 3/20 0.38
▸ CDK5 Q00535 3/20 0.38
▸ CDK5R1 Q15078 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ CDK4 P11802 2/20 0.38
▸ CCNB1 P14635 2/20 0.38
▸ CCNA2 P20248 2/20 0.38
▸ CCND1 P24385 2/20 0.38
▸ CDK7 P50613 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13513953 0.92 KCNH3 (0.39) RECQLMCL1GBA1KCNH3HTT
SCHEMBL13653062 0.88 HRH4 (0.40) KCNH3CDK1CDK2MAPTNPC1
SCHEMBL13513972 0.85 MKNK1 (0.35) KCNH3CDK1CDK2MAPTNPC1
SCHEMBL13513929 0.85 HRH4 (0.35) CDK1CDK2MAPTNPC1MAPK1
SCHEMBL13647993 0.85 CYP1A2 (0.41) SMN1; SMN2MAPK1CLK4KDM4D
SCHEMBL13647866 0.84 SIGMAR1 (0.39) HTTCDK2CCNA2CCNT1CDK9
SCHEMBL13513968 0.82 CYP2D6 (0.49) —
SCHEMBL13513950 0.80 ADORA2A (0.37) KDR
SCHEMBL13647932 0.78 ELOVL1 (0.47) MAPTMAPK1RAB9AKDRIKBKB
SCHEMBL2860959 0.78 MAPT (0.45) KCNH3EGFRMAPTNPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663211-B1 AMINOTRIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2010-01-20 — — EP disclosed
US-7598245-B2 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-06 — — US disclosed
US-7598245-B2 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-06 — — US disclosed
US-20080096901-A1 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2008-04-24 — — US disclosed
US-20080096901-A1 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2008-04-24 — — US disclosed
US-7226920-B2 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INC. (US) 2007-06-05 — — US disclosed
US-7226920-B2 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INC. (US) 2007-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096901-A1 Aminotriazole compounds useful as inhibitors of protein kinases MAP3K20, MAP3K5, MAP3K1 RECQL 3506/4885MCL1 991/4885GBA1 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback